CCBS — Castle Creek Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Annual income statement for Castle Creek Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Total Revenue | 0 | 0 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 89.8 | 26.7 |
| Operating Profit | -89.8 | -26.7 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -88.4 | -28.6 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -88.4 | -28.6 |
| Net Income Before Extraordinary Items | ||
| Net Income | -88.4 | -28.6 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -88.9 | -29.3 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -10,459 | -3,442 |
| Dividends per Share |